APO Research
Talk to an analyst

APO RESEARCH · REPORT

Angiogenesis Therapeutic Agent

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Angiogenesis Therapeutic Agent Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025198 pages

Choose your research edition.

Industry ResearchAngiogenesis Therapeutic Agent Industry Research Report 2026148 pages · $2,950 USDIndustry Growth & TrendsGlobal Angiogenesis Therapeutic Agent Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Angiogenesis Therapeutic Agent Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Angiogenesis Therapeutic Agent Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Angiogenesis Therapeutic Agent Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Angiogenesis Therapeutic Agent market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Angiogenesis Therapeutic Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Angiogenesis Therapeutic Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Angiogenesis Therapeutic Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Angiogenesis Therapeutic Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Angiogenesis Therapeutic Agent include Sun Pharma, Shanghai Pharmaceuticals, Johnson & Johnson, Novartis AG, Gilead Sciences, Inc., Pfizer, Daiichi Sankyo, Bayer AG and The Geuder Group, MORCHER GmbH, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Angiogenesis Therapeutic Agent market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Angiogenesis Therapeutic Agent and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Angiogenesis Therapeutic Agent sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Angiogenesis Therapeutic Agent market size, projected growth trends, production technologies, key applications, and end-use industries.

Angiogenesis Therapeutic Agent Segment by Company

Sun Pharma

Shanghai Pharmaceuticals

Johnson & Johnson

Novartis AG

Gilead Sciences, Inc.

Pfizer

Daiichi Sankyo

Bayer AG

The Geuder Group, MORCHER GmbH

Santen Pharmaceutical Co., Ltd.

Regeneron Pharmaceuticals, Inc.

Otsuka Pharmaceutical Co. Ltd

Novamedika

Medicom Health care

Implandata ophthalmic products GmbH

Genentech, Inc.

Eyetech Inc.

ERC Labs

Becton, Dickinson and Company

Allergan plc

Angiogenesis Therapeutic Agent Segment by Type

Diabetic Retinopathy

Myopic Choroidal Neovascularization

Macular Edema

Macular Degeneration

Angiogenesis Therapeutic Agent Segment by Application

Online Pharmacies

Hospital Pharmacies

Retail Pharmacies

Angiogenesis Therapeutic Agent Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Angiogenesis Therapeutic Agent market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Angiogenesis Therapeutic Agent and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Angiogenesis Therapeutic Agent.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Angiogenesis Therapeutic Agent market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Angiogenesis Therapeutic Agent manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Angiogenesis Therapeutic Agent in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Angiogenesis Therapeutic Agent in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Angiogenesis Therapeutic Agent Industry Trends Table 2. Angiogenesis Therapeutic Agent Industry Drivers Table 3. Angiogenesis Therapeutic Agent Industry Opportunities and Challenges Table 4. Angiogenesis Therapeutic Agent Industry Restraints Table 5. Global Angiogenesis Therapeutic Agent Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Angiogenesis Therapeutic Agent Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Angiogenesis Therapeutic Agent Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Angiogenesis Therapeutic Agent Sales Market Share by Manufacturers Table 9. Global Angiogenesis Therapeutic Agent Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Angiogenesis Therapeutic Agent Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Angiogenesis Therapeutic Agent Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Angiogenesis Therapeutic Agent Manufacturers, Product Type & Application Table 13. Global Angiogenesis Therapeutic Agent Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Angiogenesis Therapeutic Agent by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Diabetic Retinopathy Table 17. Major Manufacturers of Myopic Choroidal Neovascularization Table 18. Major Manufacturers of Macular Edema Table 19. Major Manufacturers of Macular Degeneration Table 20. Global Angiogenesis Therapeutic Agent Sales by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global Angiogenesis Therapeutic Agent Sales by Type (2021-2026) & (k units) Table 22. Global Angiogenesis Therapeutic Agent Sales by Type (2027-2032) & (k units) Table 23. Global Angiogenesis Therapeutic Agent Sales Market Share by Type (2021-2026) Table 24. Global Angiogenesis Therapeutic Agent Sales Market Share by Type (2027-2032) Table 25. Global Angiogenesis Therapeutic Agent Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 26. Global Angiogenesis Therapeutic Agent Revenue by Type (2021-2026) & (k units) Table 27. Global Angiogenesis Therapeutic Agent Revenue by Type (2027-2032) & (k units) Table 28. Global Angiogenesis Therapeutic Agent Revenue Market Share by Type (2021-2026) Table 29. Global Angiogenesis Therapeutic Agent Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Online Pharmacies Table 31. Major Manufacturers of Hospital Pharmacies Table 32. Major Manufacturers of Retail Pharmacies Table 33. Global Angiogenesis Therapeutic Agent Sales by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global Angiogenesis Therapeutic Agent Sales by Application (2021-2026) & (k units) Table 35. Global Angiogenesis Therapeutic Agent Sales by Application (2027-2032) & (k units) Table 36. Global Angiogenesis Therapeutic Agent Sales Market Share by Application (2021-2026) Table 37. Global Angiogenesis Therapeutic Agent Sales Market Share by Application (2027-2032) Table 38. Global Angiogenesis Therapeutic Agent Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 39. Global Angiogenesis Therapeutic Agent Revenue by Application (2021-2026) & (k units) Table 40. Global Angiogenesis Therapeutic Agent Revenue by Application (2027-2032) & (k units) Table 41. Global Angiogenesis Therapeutic Agent Revenue Market Share by Application (2021-2026) Table 42. Global Angiogenesis Therapeutic Agent Revenue Market Share by Application (2027-2032) Table 43. Global Angiogenesis Therapeutic Agent Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global Angiogenesis Therapeutic Agent Sales by Region (2021-2026) & (k units) Table 45. Global Angiogenesis Therapeutic Agent Sales Market Share by Region (2021-2026) Table 46. Global Angiogenesis Therapeutic Agent Sales Forecasted by Region (2027-2032) & (k units) Table 47. Global Angiogenesis Therapeutic Agent Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Angiogenesis Therapeutic Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 49. North America Angiogenesis Therapeutic Agent Sales by Country (2021-2026) & (k units) Table 50. North America Angiogenesis Therapeutic Agent Sales by Country (2027-2032) & (k units) Table 51. Europe Angiogenesis Therapeutic Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 52. Europe Angiogenesis Therapeutic Agent Sales by Country (2021-2026) & (k units) Table 53. Europe Angiogenesis Therapeutic Agent Sales by Country (2027-2032) & (k units) Table 54. Asia Pacific Angiogenesis Therapeutic Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Asia Pacific Angiogenesis Therapeutic Agent Sales by Country (2021-2026) & (k units) Table 56. Asia Pacific Angiogenesis Therapeutic Agent Sales by Country (2027-2032) & (k units) Table 57. South America, Middle East and Africa Angiogenesis Therapeutic Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 58. South America, Middle East and Africa Angiogenesis Therapeutic Agent Sales by Country (2021-2026) & (k units) Table 59. South America, Middle East and Africa Angiogenesis Therapeutic Agent Sales by Country (2027-2032) & (k units) Table 60. Global Angiogenesis Therapeutic Agent Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Angiogenesis Therapeutic Agent Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Angiogenesis Therapeutic Agent Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Angiogenesis Therapeutic Agent Revenue Market Share by Region (2021-2026) Table 64. Global Angiogenesis Therapeutic Agent Revenue Market Share by Region (2027-2032) Table 65. Sun Pharma Company Information Table 66. Sun Pharma Business Overview Table 67. Sun Pharma Angiogenesis Therapeutic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Sun Pharma Angiogenesis Therapeutic Agent Product Portfolio Table 69. Sun Pharma Recent Development Table 70. Shanghai Pharmaceuticals Company Information Table 71. Shanghai Pharmaceuticals Business Overview Table 72. Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Product Portfolio Table 74. Shanghai Pharmaceuticals Recent Development Table 75. Johnson & Johnson Company Information Table 76. Johnson & Johnson Business Overview Table 77. Johnson & Johnson Angiogenesis Therapeutic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Johnson & Johnson Angiogenesis Therapeutic Agent Product Portfolio Table 79. Johnson & Johnson Recent Development Table 80. Novartis AG Company Information Table 81. Novartis AG Business Overview Table 82. Novartis AG Angiogenesis Therapeutic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Novartis AG Angiogenesis Therapeutic Agent Product Portfolio Table 84. Novartis AG Recent Development Table 85. Gilead Sciences, Inc. Company Information Table 86. Gilead Sciences, Inc. Business Overview Table 87. Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Product Portfolio Table 89. Gilead Sciences, Inc. Recent Development Table 90. Pfizer Company Information Table 91. Pfizer Business Overview Table 92. Pfizer Angiogenesis Therapeutic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Pfizer Angiogenesis Therapeutic Agent Product Portfolio Table 94. Pfizer Recent Development Table 95. Daiichi Sankyo Company Information Table 96. Daiichi Sankyo Business Overview Table 97. Daiichi Sankyo Angiogenesis Therapeutic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Daiichi Sankyo Angiogenesis Therapeutic Agent Product Portfolio Table 99. Daiichi Sankyo Recent Development Table 100. Bayer AG Company Information Table 101. Bayer AG Business Overview Table 102. Bayer AG Angiogenesis Therapeutic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Bayer AG Angiogenesis Therapeutic Agent Product Portfolio Table 104. Bayer AG Recent Development Table 105. The Geuder Group, MORCHER GmbH Company Information Table 106. The Geuder Group, MORCHER GmbH Business Overview Table 107. The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent Product Portfolio Table 109. The Geuder Group, MORCHER GmbH Recent Development Table 110. Santen Pharmaceutical Co., Ltd. Company Information Table 111. Santen Pharmaceutical Co., Ltd. Business Overview Table 112. Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Product Portfolio Table 114. Santen Pharmaceutical Co., Ltd. Recent Development Table 115. Regeneron Pharmaceuticals, Inc. Company Information Table 116. Regeneron Pharmaceuticals, Inc. Business Overview Table 117. Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Product Portfolio Table 119. Regeneron Pharmaceuticals, Inc. Recent Development Table 120. Otsuka Pharmaceutical Co. Ltd Company Information Table 121. Otsuka Pharmaceutical Co. Ltd Business Overview Table 122. Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Product Portfolio Table 124. Otsuka Pharmaceutical Co. Ltd Recent Development Table 125. Novamedika Company Information Table 126. Novamedika Business Overview Table 127. Novamedika Angiogenesis Therapeutic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Novamedika Angiogenesis Therapeutic Agent Product Portfolio Table 129. Novamedika Recent Development Table 130. Medicom Health care Company Information Table 131. Medicom Health care Business Overview Table 132. Medicom Health care Angiogenesis Therapeutic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. Medicom Health care Angiogenesis Therapeutic Agent Product Portfolio Table 134. Medicom Health care Recent Development Table 135. Implandata ophthalmic products GmbH Company Information Table 136. Implandata ophthalmic products GmbH Business Overview Table 137. Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 138. Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent Product Portfolio Table 139. Implandata ophthalmic products GmbH Recent Development Table 140. Genentech, Inc. Company Information Table 141. Genentech, Inc. Business Overview Table 142. Genentech, Inc. Angiogenesis Therapeutic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 143. Genentech, Inc. Angiogenesis Therapeutic Agent Product Portfolio Table 144. Genentech, Inc. Recent Development Table 145. Eyetech Inc. Company Information Table 146. Eyetech Inc. Business Overview Table 147. Eyetech Inc. Angiogenesis Therapeutic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 148. Eyetech Inc. Angiogenesis Therapeutic Agent Product Portfolio Table 149. Eyetech Inc. Recent Development Table 150. ERC Labs Company Information Table 151. ERC Labs Business Overview Table 152. ERC Labs Angiogenesis Therapeutic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 153. ERC Labs Angiogenesis Therapeutic Agent Product Portfolio Table 154. ERC Labs Recent Development Table 155. Becton, Dickinson and Company Company Information Table 156. Becton, Dickinson and Company Business Overview Table 157. Becton, Dickinson and Company Angiogenesis Therapeutic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 158. Becton, Dickinson and Company Angiogenesis Therapeutic Agent Product Portfolio Table 159. Becton, Dickinson and Company Recent Development Table 160. Allergan plc Company Information Table 161. Allergan plc Business Overview Table 162. Allergan plc Angiogenesis Therapeutic Agent Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 163. Allergan plc Angiogenesis Therapeutic Agent Product Portfolio Table 164. Allergan plc Recent Development Table 165. Key Raw Materials Table 166. Raw Materials Key Suppliers Table 167. Angiogenesis Therapeutic Agent Distributors List Table 168. Angiogenesis Therapeutic Agent Customers List Table 169. Research Programs/Design for This Report Table 170. Authors List of This Report Table 171. Secondary Sources Table 172. Primary Sources List of Figures Figure 1. Angiogenesis Therapeutic Agent Product Image Figure 2. Global Angiogenesis Therapeutic Agent Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Angiogenesis Therapeutic Agent Market Size (2021-2032) & (US$ Million) Figure 4. Global Angiogenesis Therapeutic Agent Sales (2021-2032) & (k units) Figure 5. Global Angiogenesis Therapeutic Agent Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Angiogenesis Therapeutic Agent Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Diabetic Retinopathy Image Figure 9. Myopic Choroidal Neovascularization Image Figure 10. Macular Edema Image Figure 11. Macular Degeneration Image Figure 12. Global Angiogenesis Therapeutic Agent Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global Angiogenesis Therapeutic Agent Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Angiogenesis Therapeutic Agent Sales Market Share by Type (2021-2032) Figure 15. Global Angiogenesis Therapeutic Agent Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 16. Global Angiogenesis Therapeutic Agent Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Angiogenesis Therapeutic Agent Revenue Market Share by Type (2021-2032) Figure 18. Online Pharmacies Image Figure 19. Hospital Pharmacies Image Figure 20. Retail Pharmacies Image Figure 21. Global Angiogenesis Therapeutic Agent Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Angiogenesis Therapeutic Agent Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Angiogenesis Therapeutic Agent Sales Market Share by Application (2021-2032) Figure 24. Global Angiogenesis Therapeutic Agent Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 25. Global Angiogenesis Therapeutic Agent Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Angiogenesis Therapeutic Agent Revenue Market Share by Application (2021-2032) Figure 27. North America Angiogenesis Therapeutic Agent Sales and Growth Rate (2021-2032) & (k units) Figure 28. North America Angiogenesis Therapeutic Agent Sales Market Share by Country (2021-2032) Figure 29. U.S. Angiogenesis Therapeutic Agent Sales and Growth Rate (2021-2032) & (k units) Figure 30. Canada Angiogenesis Therapeutic Agent Sales and Growth Rate (2021-2032) & (k units) Figure 31. Mexico Angiogenesis Therapeutic Agent Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe Angiogenesis Therapeutic Agent Sales and Growth Rate (2021-2032) & (k units) Figure 33. Europe Angiogenesis Therapeutic Agent Sales Market Share by Country (2021-2032) Figure 34. Germany Angiogenesis Therapeutic Agent Sales and Growth Rate (2021-2032) & (k units) Figure 35. France Angiogenesis Therapeutic Agent Sales and Growth Rate (2021-2032) & (k units) Figure 36. U.K. Angiogenesis Therapeutic Agent Sales and Growth Rate (2021-2032) & (k units) Figure 37. Italy Angiogenesis Therapeutic Agent Sales and Growth Rate (2021-2032) & (k units) Figure 38. Netherlands Angiogenesis Therapeutic Agent Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific Angiogenesis Therapeutic Agent Sales and Growth Rate (2021-2032) & (k units) Figure 40. Asia Pacific Angiogenesis Therapeutic Agent Sales Market Share by Country (2021-2032) Figure 41. China Angiogenesis Therapeutic Agent Sales and Growth Rate (2021-2032) & (k units) Figure 42. Japan Angiogenesis Therapeutic Agent Sales and Growth Rate (2021-2032) & (k units) Figure 43. South Korea Angiogenesis Therapeutic Agent Sales and Growth Rate (2021-2032) & (k units) Figure 44. Southeast Asia Angiogenesis Therapeutic Agent Sales and Growth Rate (2021-2032) & (k units) Figure 45. India Angiogenesis Therapeutic Agent Sales and Growth Rate (2021-2032) & (k units) Figure 46. Australia Angiogenesis Therapeutic Agent Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa Angiogenesis Therapeutic Agent Sales and Growth Rate (2021-2032) & (k units) Figure 48. South America, Middle East and Africa Angiogenesis Therapeutic Agent Sales Market Share by Country (2021-2032) Figure 49. Brazil Angiogenesis Therapeutic Agent Sales and Growth Rate (2021-2032) & (k units) Figure 50. South Africa Angiogenesis Therapeutic Agent Sales and Growth Rate (2021-2032) & (k units) Figure 51. Saudi Arabia Angiogenesis Therapeutic Agent Sales and Growth Rate (2021-2032) & (k units) Figure 52. Turkey Angiogenesis Therapeutic Agent Sales and Growth Rate (2021-2032) & (k units) Figure 53. Argentina Angiogenesis Therapeutic Agent Sales and Growth Rate (2021-2032) & (k units) Figure 54. UAE Angiogenesis Therapeutic Agent Sales and Growth Rate (2021-2032) & (k units) Figure 55. Egypt Angiogenesis Therapeutic Agent Sales and Growth Rate (2021-2032) & (k units) Figure 56. Chile Angiogenesis Therapeutic Agent Sales and Growth Rate (2021-2032) & (k units) Figure 57. Global Angiogenesis Therapeutic Agent Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Angiogenesis Therapeutic Agent Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Angiogenesis Therapeutic Agent Revenue (2021-2032) & (US$ Million) Figure 60. North America Angiogenesis Therapeutic Agent Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Angiogenesis Therapeutic Agent Revenue (2021-2032) & (US$ Million) Figure 62. Europe Angiogenesis Therapeutic Agent Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Angiogenesis Therapeutic Agent Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Angiogenesis Therapeutic Agent Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Angiogenesis Therapeutic Agent Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Angiogenesis Therapeutic Agent Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Angiogenesis Therapeutic Agent Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Angiogenesis Therapeutic Agent Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Diabetic Retinopathy
  • Myopic Choroidal Neovascularization
  • Macular Edema
  • Macular Degeneration
Applications
  • Online Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies
Companies covered
  • Sun Pharma
  • Shanghai Pharmaceuticals
  • Johnson & Johnson
  • Novartis AG
  • Gilead Sciences, Inc.
  • Pfizer
  • Daiichi Sankyo
  • Bayer AG
  • The Geuder Group, MORCHER GmbH
  • Santen Pharmaceutical Co., Ltd.
  • Regeneron Pharmaceuticals, Inc.
  • Otsuka Pharmaceutical Co. Ltd
  • Novamedika
  • Medicom Health care
  • Implandata ophthalmic products GmbH
  • Genentech, Inc.
  • Eyetech Inc.
  • ERC Labs
  • Becton, Dickinson and Company
  • Allergan plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Angiogenesis Therapeutic Agent Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Angiogenesis Therapeutic Agent Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Angiogenesis Therapeutic Agent Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Angiogenesis Therapeutic Agent Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Angiogenesis Therapeutic Agent Market Dynamics
  1. 2.1 Angiogenesis Therapeutic Agent Industry Trends
  2. 2.2 Angiogenesis Therapeutic Agent Industry Drivers
  3. 2.3 Angiogenesis Therapeutic Agent Industry Opportunities and Challenges
  4. 2.4 Angiogenesis Therapeutic Agent Industry Restraints
3 Angiogenesis Therapeutic Agent Market by Manufacturers
  1. 3.1 Global Angiogenesis Therapeutic Agent Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Angiogenesis Therapeutic Agent Sales by Manufacturers (2021-2026)
  3. 3.3 Global Angiogenesis Therapeutic Agent Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Angiogenesis Therapeutic Agent Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Angiogenesis Therapeutic Agent Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Angiogenesis Therapeutic Agent Manufacturers, Product Type & Application
  7. 3.7 Global Angiogenesis Therapeutic Agent Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Angiogenesis Therapeutic Agent Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Angiogenesis Therapeutic Agent Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Angiogenesis Therapeutic Agent Tier 1, Tier 2, and Tier 3
4 Angiogenesis Therapeutic Agent Market by Type
  1. 4.1 Angiogenesis Therapeutic Agent Type Introduction
  2. 4.1.1 Diabetic Retinopathy
  3. 4.1.2 Myopic Choroidal Neovascularization
  4. 4.1.3 Macular Edema
  5. 4.1.4 Macular Degeneration
  6. 4.2 Global Angiogenesis Therapeutic Agent Sales by Type
  7. 4.2.1 Global Angiogenesis Therapeutic Agent Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Angiogenesis Therapeutic Agent Sales by Type (2021-2032)
  9. 4.2.3 Global Angiogenesis Therapeutic Agent Sales Market Share by Type (2021-2032)
  10. 4.3 Global Angiogenesis Therapeutic Agent Revenue by Type
  11. 4.3.1 Global Angiogenesis Therapeutic Agent Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Angiogenesis Therapeutic Agent Revenue by Type (2021-2032)
  13. 4.3.3 Global Angiogenesis Therapeutic Agent Revenue Market Share by Type (2021-2032)
5 Angiogenesis Therapeutic Agent Market by Application
  1. 5.1 Angiogenesis Therapeutic Agent Application Introduction
  2. 5.1.1 Online Pharmacies
  3. 5.1.2 Hospital Pharmacies
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global Angiogenesis Therapeutic Agent Sales by Application
  6. 5.2.1 Global Angiogenesis Therapeutic Agent Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Angiogenesis Therapeutic Agent Sales by Application (2021-2032)
  8. 5.2.3 Global Angiogenesis Therapeutic Agent Sales Market Share by Application (2021-2032)
  9. 5.3 Global Angiogenesis Therapeutic Agent Revenue by Application
  10. 5.3.1 Global Angiogenesis Therapeutic Agent Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Angiogenesis Therapeutic Agent Revenue by Application (2021-2032)
  12. 5.3.3 Global Angiogenesis Therapeutic Agent Revenue Market Share by Application (2021-2032)
6 Global Angiogenesis Therapeutic Agent Sales by Region
  1. 6.1 Global Angiogenesis Therapeutic Agent Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Angiogenesis Therapeutic Agent Sales by Region (2021-2032)
  3. 6.2.1 Global Angiogenesis Therapeutic Agent Sales by Region (2021-2026)
  4. 6.2.2 Global Angiogenesis Therapeutic Agent Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Angiogenesis Therapeutic Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Angiogenesis Therapeutic Agent Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Angiogenesis Therapeutic Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Angiogenesis Therapeutic Agent Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Angiogenesis Therapeutic Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Angiogenesis Therapeutic Agent Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Angiogenesis Therapeutic Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Angiogenesis Therapeutic Agent Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Angiogenesis Therapeutic Agent Revenue by Region
  1. 7.1 Global Angiogenesis Therapeutic Agent Revenue by Region
  2. 7.1.1 Global Angiogenesis Therapeutic Agent Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Angiogenesis Therapeutic Agent Revenue by Region (2021-2026)
  4. 7.1.3 Global Angiogenesis Therapeutic Agent Revenue by Region (2027-2032)
  5. 7.1.4 Global Angiogenesis Therapeutic Agent Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Angiogenesis Therapeutic Agent Revenue (2021-2032)
  8. 7.2.2 North America Angiogenesis Therapeutic Agent Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Angiogenesis Therapeutic Agent Revenue (2021-2032)
  11. 7.3.2 Europe Angiogenesis Therapeutic Agent Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Angiogenesis Therapeutic Agent Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Angiogenesis Therapeutic Agent Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Angiogenesis Therapeutic Agent Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Angiogenesis Therapeutic Agent Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Sun Pharma
  2. 8.1.1 Sun Pharma Company Information
  3. 8.1.2 Sun Pharma Business Overview
  4. 8.1.3 Sun Pharma Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sun Pharma Angiogenesis Therapeutic Agent Product Portfolio
  6. 8.1.5 Sun Pharma Recent Developments
  7. 8.2 Shanghai Pharmaceuticals
  8. 8.2.1 Shanghai Pharmaceuticals Company Information
  9. 8.2.2 Shanghai Pharmaceuticals Business Overview
  10. 8.2.3 Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Product Portfolio
  12. 8.2.5 Shanghai Pharmaceuticals Recent Developments
  13. 8.3 Johnson & Johnson
  14. 8.3.1 Johnson & Johnson Company Information
  15. 8.3.2 Johnson & Johnson Business Overview
  16. 8.3.3 Johnson & Johnson Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Johnson & Johnson Angiogenesis Therapeutic Agent Product Portfolio
  18. 8.3.5 Johnson & Johnson Recent Developments
  19. 8.4 Novartis AG
  20. 8.4.1 Novartis AG Company Information
  21. 8.4.2 Novartis AG Business Overview
  22. 8.4.3 Novartis AG Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis AG Angiogenesis Therapeutic Agent Product Portfolio
  24. 8.4.5 Novartis AG Recent Developments
  25. 8.5 Gilead Sciences, Inc.
  26. 8.5.1 Gilead Sciences, Inc. Company Information
  27. 8.5.2 Gilead Sciences, Inc. Business Overview
  28. 8.5.3 Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Product Portfolio
  30. 8.5.5 Gilead Sciences, Inc. Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Angiogenesis Therapeutic Agent Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Daiichi Sankyo
  38. 8.7.1 Daiichi Sankyo Company Information
  39. 8.7.2 Daiichi Sankyo Business Overview
  40. 8.7.3 Daiichi Sankyo Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Daiichi Sankyo Angiogenesis Therapeutic Agent Product Portfolio
  42. 8.7.5 Daiichi Sankyo Recent Developments
  43. 8.8 Bayer AG
  44. 8.8.1 Bayer AG Company Information
  45. 8.8.2 Bayer AG Business Overview
  46. 8.8.3 Bayer AG Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Bayer AG Angiogenesis Therapeutic Agent Product Portfolio
  48. 8.8.5 Bayer AG Recent Developments
  49. 8.9 The Geuder Group, MORCHER GmbH
  50. 8.9.1 The Geuder Group, MORCHER GmbH Company Information
  51. 8.9.2 The Geuder Group, MORCHER GmbH Business Overview
  52. 8.9.3 The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent Product Portfolio
  54. 8.9.5 The Geuder Group, MORCHER GmbH Recent Developments
  55. 8.10 Santen Pharmaceutical Co., Ltd.
  56. 8.10.1 Santen Pharmaceutical Co., Ltd. Company Information
  57. 8.10.2 Santen Pharmaceutical Co., Ltd. Business Overview
  58. 8.10.3 Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Product Portfolio
  60. 8.10.5 Santen Pharmaceutical Co., Ltd. Recent Developments
  61. 8.11 Regeneron Pharmaceuticals, Inc.
  62. 8.11.1 Regeneron Pharmaceuticals, Inc. Company Information
  63. 8.11.2 Regeneron Pharmaceuticals, Inc. Business Overview
  64. 8.11.3 Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Product Portfolio
  66. 8.11.5 Regeneron Pharmaceuticals, Inc. Recent Developments
  67. 8.12 Otsuka Pharmaceutical Co. Ltd
  68. 8.12.1 Otsuka Pharmaceutical Co. Ltd Company Information
  69. 8.12.2 Otsuka Pharmaceutical Co. Ltd Business Overview
  70. 8.12.3 Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Product Portfolio
  72. 8.12.5 Otsuka Pharmaceutical Co. Ltd Recent Developments
  73. 8.13 Novamedika
  74. 8.13.1 Novamedika Company Information
  75. 8.13.2 Novamedika Business Overview
  76. 8.13.3 Novamedika Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Novamedika Angiogenesis Therapeutic Agent Product Portfolio
  78. 8.13.5 Novamedika Recent Developments
  79. 8.14 Medicom Health care
  80. 8.14.1 Medicom Health care Company Information
  81. 8.14.2 Medicom Health care Business Overview
  82. 8.14.3 Medicom Health care Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Medicom Health care Angiogenesis Therapeutic Agent Product Portfolio
  84. 8.14.5 Medicom Health care Recent Developments
  85. 8.15 Implandata ophthalmic products GmbH
  86. 8.15.1 Implandata ophthalmic products GmbH Company Information
  87. 8.15.2 Implandata ophthalmic products GmbH Business Overview
  88. 8.15.3 Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent Product Portfolio
  90. 8.15.5 Implandata ophthalmic products GmbH Recent Developments
  91. 8.16 Genentech, Inc.
  92. 8.16.1 Genentech, Inc. Company Information
  93. 8.16.2 Genentech, Inc. Business Overview
  94. 8.16.3 Genentech, Inc. Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Genentech, Inc. Angiogenesis Therapeutic Agent Product Portfolio
  96. 8.16.5 Genentech, Inc. Recent Developments
  97. 8.17 Eyetech Inc.
  98. 8.17.1 Eyetech Inc. Company Information
  99. 8.17.2 Eyetech Inc. Business Overview
  100. 8.17.3 Eyetech Inc. Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Eyetech Inc. Angiogenesis Therapeutic Agent Product Portfolio
  102. 8.17.5 Eyetech Inc. Recent Developments
  103. 8.18 ERC Labs
  104. 8.18.1 ERC Labs Company Information
  105. 8.18.2 ERC Labs Business Overview
  106. 8.18.3 ERC Labs Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 ERC Labs Angiogenesis Therapeutic Agent Product Portfolio
  108. 8.18.5 ERC Labs Recent Developments
  109. 8.19 Becton, Dickinson and Company
  110. 8.19.1 Becton, Dickinson and Company Company Information
  111. 8.19.2 Becton, Dickinson and Company Business Overview
  112. 8.19.3 Becton, Dickinson and Company Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Becton, Dickinson and Company Angiogenesis Therapeutic Agent Product Portfolio
  114. 8.19.5 Becton, Dickinson and Company Recent Developments
  115. 8.20 Allergan plc
  116. 8.20.1 Allergan plc Company Information
  117. 8.20.2 Allergan plc Business Overview
  118. 8.20.3 Allergan plc Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Allergan plc Angiogenesis Therapeutic Agent Product Portfolio
  120. 8.20.5 Allergan plc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Angiogenesis Therapeutic Agent Value Chain Analysis
  2. 9.1.1 Angiogenesis Therapeutic Agent Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Angiogenesis Therapeutic Agent Production Mode & Process
  6. 9.2 Angiogenesis Therapeutic Agent Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Angiogenesis Therapeutic Agent Distributors
  9. 9.2.3 Angiogenesis Therapeutic Agent Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst